Treatment of Heart failure with preserved EF

diuresis, Rx HTN, tachycardia, and ischemia

SGLT2i ↓ CV death or HF hosp (NEJM 2021;385:1451; DELIVER)

Nonsignficiant trends toward benefit for ARB vs. placebo. ARNI ↓ CV death or hosp for HF in HFpEF Pts w/ LVEF <60% (NEJM 2019; 381:1609)

Spironolactone likely ↓ HF hospitalization (NEJM 2014;370:1383; Circ 2015;131:34)